Avenciguat
Avenciguat[edit | edit source]
Avenciguat is a pharmaceutical compound that acts as a soluble guanylate cyclase (sGC) stimulator. It is primarily investigated for its potential therapeutic effects in treating heart failure and other cardiovascular conditions. Avenciguat is part of a class of drugs that target the nitric oxide (NO) signaling pathway, which plays a crucial role in vascular homeostasis and cardiac function.
Mechanism of Action[edit | edit source]
Avenciguat works by stimulating soluble guanylate cyclase, an enzyme that is activated by nitric oxide. This enzyme catalyzes the conversion of GTP to cyclic GMP (cGMP), a secondary messenger that mediates various physiological processes. By increasing cGMP levels, avenciguat promotes vasodilation, reduces vascular resistance, and improves cardiac output. This mechanism is particularly beneficial in conditions where nitric oxide signaling is impaired, such as in heart failure.
Clinical Development[edit | edit source]
Avenciguat is currently under investigation in clinical trials for its efficacy and safety in treating heart failure with preserved ejection fraction (HFpEF) and other cardiovascular diseases. The drug is being evaluated for its ability to improve exercise capacity, reduce symptoms, and enhance quality of life in patients with heart failure.
Potential Benefits[edit | edit source]
The potential benefits of avenciguat include:
- Improved Cardiac Function: By enhancing cGMP signaling, avenciguat may improve myocardial relaxation and reduce cardiac hypertrophy.
- Vasodilation: The drug promotes vasodilation, which can lower blood pressure and reduce the workload on the heart.
- Symptom Relief: Patients may experience relief from symptoms such as shortness of breath and fatigue.
Side Effects[edit | edit source]
As with any medication, avenciguat may cause side effects. Common side effects observed in clinical trials include headache, dizziness, and hypotension. It is important for patients to be monitored for these effects, especially when starting the medication or adjusting the dose.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
